From Cannabis MSO To Drug Development: Goodness Growth Wants To Understand Traditional Psychedelics Use

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings, Inc. GDNS GDNSF, is launching a survey study that will look into the varying effects of entheogen and psychedelic experiences for therapeutic, religious and spiritual purposes.

The goal of the company is to understand the naturalistic use of entheogens and other substances typically used for healing in specific cultural and spiritual contexts.

Goodness Growth recently changed its name from Vireo Health in a move to encompass the psychedelics and natural medicine space, expanding beyond its cannabis MSO operations.

A Survey Into Traditional Psychedelics Use

The study’s approach seeks to complement current research into psychedelics, which is often done with synthetic substances (like MDMA, LSD or isolated psilocybin), in a strictly clinical context.

“Lab-based research will always be an essential aspect of our research and development process. However, to create more effective psychedelic-based therapies and services, we believe it is equally important to thoroughly explore the tremendous wealth of experience and wisdom that already exists and is active today based on centuries of both spiritual and therapeutic practices,” said chief medical officer Stephen Dahmer.

The observational pilot survey, which will be done online with one hundred anonymous subjects, has received approval from an independent Institutional Review Board registered with the Office for Human Research Protections at the federal Department of Health and Human Services.

According to the FDA, an Institutional Review Board is an “appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects.”

The board has the authority to approve, require modifications or disapprove research. Its aim is to protect the rights and welfare of human research subjects.

The survey will help inform Resurgent on future developments into psychedelic-based therapies by collecting anonymous data from 100 adults who self-report having participated in entheogen therapy centers and retreats during the last five years.
The survey currently is open for participation via this link.

Photo by Vlada Karpovich from Pexels.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksFDAMarketsResurgent BiosciencesStephen Dahmer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...